ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 38 of 486 for:    stem cell pulmonary disease

An Exploratory Study on the Treatment of Chronic Obstructive Pulmonary Disease With Autologous Bronchial Basal Cell Transplantation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03021681
Recruitment Status : Recruiting
First Posted : January 16, 2017
Last Update Posted : January 24, 2017
Sponsor:
Collaborator:
Regend Therapeutics
Information provided by (Responsible Party):
ZiLi Meng, Huai'an No.1 People's Hospital

Brief Summary:
Chronic obstructive pulmonary disease(COPD)is characterized by recurrent cough, expectoration and asthma, and eventually develop chronic pulmonary heart disease ,chronic respiratory failure and even death. The current clinical treatments for these patients are symptomatic treatment cannot solve the problem of the damaged lung structure fundamentally. Recent studies show that bronchial basement the layer of cells is a kind of cells in the bronchial epithelial basal layer position, the specific expression of Krt5 antigen with the regeneration and repair of lung function , these cells have the activity similar to adult tissue stem cells. Its division and migration are more active and can continue to produce new cells to complement the death of other types of epithelial cells with functional plasticity which can be used to direct repair the bronchial and alveolar structures. It has been proved that bronchial basal cell transplantation can repair the damaged lungs of experimental animals . The bronchial basal cells from autologous tissue, so there is no immune rejection problem. Also because the bronchial basal cells derived from adult tissues which is a part of the body, so there is no risk of a tumor (in animal experiments, In animal experiments, bronchial basal cells transtracheal input 100 times in human dose still no tumor formation). In the early stage, patients with COPD (2 cases), bronchiectasis (2 cases) and interstitial lung disease (1 case) received the treatment, and the overall effect was good. Diseases were alleviated and recovered to some different extend.The study was to brush bronchial basal cells through fiberbronchoscopy in COPD patients and cultured in vitro, and then through the bronchoscope transfusion to the lesion site. To preliminary evaluate the efficacy and safety of autologous bronchial basal cells in the treatment of chronic obstructive pulmonary disease.

Condition or disease Intervention/treatment Phase
Cell Transplantation Other: autologous bronchial basal cell transplantation Not Applicable

Detailed Description:
Between November 2016 and November 2019, the investigators initially recruited 20 with stable COPD patients. Primary evaluations including medical history, physical examination, anthropometric data, blood routine, blood biochemistry, blood coagulation, electrocardiogram,high resolution chest CT, arterial blood gas, pulmonary function test,6-min walking test(6MWT),modified medical research council(MMRC),St George's respiratory questionnaire(SGRQ). After initial evaluation, the investigators obtained extraction bronchial basal cells micro tissue from 3~4 grade bronchus to by mean of fiberbronchoscopy, then purified and selectively amplified bronchial basal cells to reserve .The basal layer cell culture system for our partners (Regend Therapeutics) patented technology using culture medium containing special combination of growth factors and composite materials to simulated composite basal layer environment and can selectively amplified bronchial basal cells, while other types of mature epithelial cells and fibroblasts could not grow naturally. After a period of time, the basal lamina of the bronchial epithelial cells can be stored in the liquid nitrogen cell bank for a long time. Before applied to the patient, bronchial basal cells need to go through a series of strict examination. Then, bronchoscopy was performed again and the bronchial basal lamina suspension was injected directly into the lesion site . Estimate the change of respiratory function(symptoms, signs, chest CT, pulmonary function, the 6 minute walk test, MMRC, SGRQ etc) and serum index in third days , first months, third months, sixth months and first years of the follow-up after treatment respectively, to evaluate the safety and efficiency of autologous bronchial basal cells for treatment of COPD .

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Huai'an First People 's Hospital,Nanjing Medical University
Study Start Date : November 2016
Estimated Primary Completion Date : November 2019
Estimated Study Completion Date : November 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: COPD Lung Diseases

Arm Intervention/treatment
COPD group(self control)
Prior treatment:20 stable COPD patients were enrolled,estimated the respiratory function and serum index Intervention:autologous bronchial basal cell transplantation After treatment:Estimate the change of respiratory function and serum index in third days , first months, third months, sixth months and first years of the follow-up after treatment respectively
Other: autologous bronchial basal cell transplantation
the investigators obtained extraction bronchial basal cells micro tissue from 3~4 grade bronchus, then purified and selectively amplified bronchial basal cells to reserve . After a period of time, the basal lamina of the bronchial epithelial cells can be stored in the liquid nitrogen cell bank for a long time. Before applied to the patient, bronchial basal cells need to go through a series of strict examination. Then, bronchoscopy was performed again and the bronchial basal lamina suspension was injected directly into the lesion site .




Primary Outcome Measures :
  1. forced expiratory volume in one second(FEV1) [ Time Frame: 24 months ]
    as the severity of chronic obstructive pulmonary disease(COPD)estimated by pulmonary function

  2. chest high-resolution computed tomography [ Time Frame: 24 months ]
    as the severity of lung hyperinflation estimated by radiological

  3. arterial blood gas [ Time Frame: 24 months ]
    to assess the level of hypoxemia and hypercapnia in chronic obstructive pulmonary disease(COPD) patients

  4. 6MWT [ Time Frame: 24 months ]
    6 min walking test, to evaluate the exercise function in patients with moderate and severe pulmonary heart diseases


Secondary Outcome Measures :
  1. forced vital capacity(FVC) [ Time Frame: 24 months ]
    an index of pulmonary function in chronic obstructive pulmonary disease(COPD) patients

  2. MMRC [ Time Frame: 24 months ]
    an index to evaluate the lever of dyspnea

  3. SGRQ [ Time Frame: 24 months ]
    a questionnaire to assess the influence of chronic airflow restriction on the quality of life, including symptoms, activities and daily life affected by diseases



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. aged between 18 to 70 years
  2. according to the guideline criteria, the diagnosis of COPD:

    ①There is a chronic cough, sputum or gas breathing symptoms such as promoting

    ②Pulmonary function tests showed airflow limitation(FEV1<80% predicted value,FEV1/FVC<0.7)

  3. CT imaging and hematological examination excluded other lung diseases.
  4. stable disease for more than 2 weeks
  5. patients who were able to tolerate fiberoptic bronchoscopy
  6. to sign the informed consent form

Exclusion Criteria:

  1. women who are pregnant, nursing or not taking effective contraception
  2. syphilis, HIV antibody positive person
  3. there is a history of alcohol or illicit drug abuse
  4. patients who had received any other clinical trial within the first 3 months
  5. poor compliance, it is difficult to complete the study
  6. researchers believe there may be any increase in the risk of the subject or any interference with the clinical trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03021681


Contacts
Contact: ZiLi Meng, Master +8613952399232 xj680390@126.com
Contact: Wei Zuo, PhD +8618516646797 zuow@regend.cn

Locations
China, Jiangsu
Huai'an First People's Hospital Recruiting
Huai'an, Jiangsu, China, 223300
Contact: ZiLi Meng, Master    +8613952399232    xj680390@126.com   
Contact: Wei Zuo, PhD    +8618516646797    zuow@regend.cn   
Principal Investigator: ZiLi Meng, Master         
Principal Investigator: Wei Zuo, PhD         
Sponsors and Collaborators
Huai'an No.1 People's Hospital
Regend Therapeutics
Investigators
Study Chair: Wei Zuo, PhD Regend Therapeutics,Suzhou Industry Park,Suzhou,CHINA